Biogen (BIIB) vs Revolution Medicines (RVMD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Revolution Medicines (RVMD) has outperformed Biogen (BIIB) over the past year, gaining 293.4% versus a gain of 44.7%. Over five years, RVMD leads with a +598.0% price change compared with -22.3% for BIIB. Revolution Medicines is the larger company by market cap ($40.87 billion vs $33.37 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIIB | RVMD |
|---|---|---|
| Share price | $225.85 | $190.66 |
| Market cap | $33.37B | $40.87B |
| 1-day change | +3.39% | +1.35% |
| YTD return | +24.12% | +136.18% |
| 1-year return | +44.68% | +293.39% |
| 5-year return | -22.32% | +598.03% |
| P/E ratio (TTM) | 40.11 | — |
| Forward P/E | 13.65 | — |
| EPS (TTM) | $5.63 | $-8.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $9.89B | $0 |
| Revenue growth (YoY) | +2.22% | — |
| Net income (latest FY) | $1.29B | $-1.13B |
| Gross margin | 75.69% | — |
| Net margin | 13.07% | — |
| 52-week high | $230.49 | $224.31 |
| 52-week low | $138.00 | $47.28 |
| Distance from 52-week high | -2.02% | -15.00% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +5.46% | +35.76% |
| Average volume | 1.06M | 1.93M |
| Shares outstanding | 147.75M | 214.34M |
| Employees | 7,500 | 883 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RVMD has outperformed BIIB by 248.7 percentage points over the past year.
About Biogen
BIIB stock →Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 7,500 employees
About Revolution Medicines
RVMD stock →Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 883 employees
BIIB vs RVMD FAQ
Which is bigger, Biogen or Revolution Medicines?
Revolution Medicines (RVMD) is larger, with a market capitalization of $40.87B compared with $33.37B for Biogen (BIIB).
Which stock has performed better over the past year, BIIB or RVMD?
RVMD returned +293.39% over the past 12 months, compared with +44.68% for BIIB (price return, excluding dividends). Past performance does not predict future results.
Are Biogen and Revolution Medicines in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.